Patent classifications
C07D241/44
Substituted quinolines as modulators of sodium channels
The invention relates to compounds of formula I or pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels: ##STR00001##
The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain.
Substituted quinolines as modulators of sodium channels
The invention relates to compounds of formula I or pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels: ##STR00001##
The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain.
MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL
Compounds comprising piperazines, piperidines, spiro-furanopiperidines, and analogs thereof are provided that are modulators, such as positive allosteric modulators, of one or more subclasses of vasopressin receptors. The compounds can be selective modulators of one or more subclasses of vasopressin receptors. Compounds of the invention can be used in the treatment of a condition wherein modulating a vasopressin receptor is medically indicated for treatment of the condition.
MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL
Compounds comprising piperazines, piperidines, spiro-furanopiperidines, and analogs thereof are provided that are modulators, such as positive allosteric modulators, of one or more subclasses of vasopressin receptors. The compounds can be selective modulators of one or more subclasses of vasopressin receptors. Compounds of the invention can be used in the treatment of a condition wherein modulating a vasopressin receptor is medically indicated for treatment of the condition.
Bicyclic sulfonamide compounds as sodium channel inhibitors
The present invention provides compounds of Formula I or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention. ##STR00001##
Bicyclic sulfonamide compounds as sodium channel inhibitors
The present invention provides compounds of Formula I or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention. ##STR00001##
Compositions of protein receptor tyrosine kinase inhibitors
The present invention relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, Tropomysosin Related Kinases (Trk), in particular the nerve growth factor (NGF) receptor, TrkA. The invention further concerns the use of such compounds in the treatment and/or prevention of pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder or injury relating to dysmyelination or demyelination or the disease or disorder associated with abnormal activities of NGF receptor TrkA.
Compositions of protein receptor tyrosine kinase inhibitors
The present invention relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, Tropomysosin Related Kinases (Trk), in particular the nerve growth factor (NGF) receptor, TrkA. The invention further concerns the use of such compounds in the treatment and/or prevention of pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder or injury relating to dysmyelination or demyelination or the disease or disorder associated with abnormal activities of NGF receptor TrkA.
COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING
The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being:
##STR00001##
where: R independently represents a hydrogen atom, a halogen atom, a (C.sub.1-C.sub.3)alkyl group, a —CN group, a hydroxyl group, a —COOR.sub.1 group, a (C.sub.1-C.sub.3)fluoroalkyl group, a —NO.sub.2 group, a —NR.sub.1R.sub.2 group, or a (C.sub.1-C.sub.3)alkoxy group; R′ is a hydrogen atom, a halogen atom, a (C.sub.1-C.sub.3)alkyl group, a —NO.sub.2 group, a (C.sub.1-C.sub.3)alkoxy group, or a —NR.sub.1R.sub.2 group; and R.sub.1 and R.sub.2 are a hydrogen atom or a (C.sub.1-C.sub.3) alkyl group.
COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING
The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being:
##STR00001##
where: R independently represents a hydrogen atom, a halogen atom, a (C.sub.1-C.sub.3)alkyl group, a —CN group, a hydroxyl group, a —COOR.sub.1 group, a (C.sub.1-C.sub.3)fluoroalkyl group, a —NO.sub.2 group, a —NR.sub.1R.sub.2 group, or a (C.sub.1-C.sub.3)alkoxy group; R′ is a hydrogen atom, a halogen atom, a (C.sub.1-C.sub.3)alkyl group, a —NO.sub.2 group, a (C.sub.1-C.sub.3)alkoxy group, or a —NR.sub.1R.sub.2 group; and R.sub.1 and R.sub.2 are a hydrogen atom or a (C.sub.1-C.sub.3) alkyl group.